Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

Publication files not online:

Author: Bernhagen, J. · Krohn, R. · Lue, H. · Gregory, J.L. · Zernecke, A. · Koenen, R.R. · Dewor, M. · Georgiev, I. · Schober, A. · Leng, L. · Kooistra, T. · Fingerle-Rowson, G. · Ghezzi, P. · Kleemann, R. · McColl, S.R. · Bucala, R. · Hickey, M.J. · Weber, C.
Type:article
Date:2007
Institution: TNO Kwaliteit van Leven
Source:Nature Medicine, 5, 13, 587-596
Identifier: 239971
doi: doi:10.1038/nm1567
Keywords: Biology · Biomedical Research · T lymphocyte · Aorta · Atherosclerosis · Chemotaxis · Endothelium, Vascular · Humans · Inflammation · Leukocytes · Ligands · Macrophage Migration-Inhibitory Factors · Monocytes · Receptors, CXCR4 · Receptors, Interleukin-8B · T-Lymphocytes · Mus

Abstract

The cytokine macrophage migration inhibitory factor (MIF) plays a critical role in inflammatory diseases and atherogenesis. We identify the chemokine receptors CXCR2 and CXCR4 as functional receptors for MIF. MIF triggered G αi- and integrin-dependent arrest and chemotaxis of monocytes and T cells, rapid integrin activation and calcium influx through CXCR2 or CXCR4. MIF competed with cognate ligands for CXCR4 and CXCR2 binding, and directly bound to CXCR2. CXCR2 and CD74 formed a receptor complex, and monocyte arrest elicited by MIF in inflamed or atherosclerotic arteries involved both CXCR2 and CD74. In vivo, Mif deficiency impaired monocyte adhesion to the arterial wall in atherosclerosis-prone mice, and MIF-induced leukocyte recruitment required Il8rb (which encodes Cxcr2). Blockade of Mif but not of canonical ligands of Cxcr2 or Cxcr4 in mice with advanced atherosclerosis led to plaque regression and reduced monocyte and T-cell content in plaques. By activating both CXCR2 and CXCR4, MIF displays chemokine-like functions and acts as a major regulator of inflammatory cell recruitment and atherogenesis. Targeting MIF in individuals with manifest atherosclerosis can potentially be used to treat this condition. © 2007 Nature Publishing Group.